Journals / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment

Pages
85–93
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The RA diagnosis delay was associated with rural geographic environment (p=0.02), lack of social insurance (p=0.027), progressive symptoms onset (p=0.006), morning stiffness (p=0.023), being initially examined by a GP (p=0.02), number of consultations (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to assess the different delays of rheumatoid arthritis (RA) patients’ journey from disease onset to treatment initiation and to identify possible influencing factors.
📊
Key Findings & Data:Patients and methods: This cross-sectional study included a total of 100 patients (14 males, 86 females; mean age: 56.5±12.4 years; range, 26 to 82 years) who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA between January 2019 and January 2020.
💡
Conclusion & Impact:The RA diagnosis delay was associated with rural geographic environment (p=0.02), lack of social insurance (p=0.027), progressive symptoms onset (p=0.006), morning stiffness (p=0.023), being initially examined by a GP (p=0.02), number of consultations (p
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to assess the different delays of rheumatoid arthritis (RA) patients’ journey from disease onset to treatment initiation and to identify possible influencing factors. Patients and methods: This cross-sectional study included a total of 100 patients (14 males, 86 females; mean age: 56.5±12.4 years; range, 26 to 82 years) who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA between January 2019 and January 2020. Demographic and clinical data and disease characteristics were collected from the patient interviews and medical files. Five different intervals were defined from symptom onset until the initiation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Results: The mean age at RA onset was 46.6±12.4 years. Median delays from onset of symptoms until general practitioner (GP) and rheumatologist consultations were six (range, 0.25 to 240) months and 12 (range, 0 to 242) months, respectively. Median delays from onset of symptoms to RA diagnosis and treatment with csDMARDs were 15.7 (range, 2 to 252) months and 18 (range, 2 to 270) months, respectively. The mean number of consultations was 7.3±4.2 and the median number of physicians visited before the diagnosis was three (range, 1 to 8). The RA diagnosis delay was associated with rural geographic environment (p=0.02), lack of social insurance (p=0.027), progressive symptoms onset (p=0.006), morning stiffness (p=0.023), being initially examined by a GP (p=0.02), number of consultations (p

🔖

Cite This Article

MILADI, S., OUENNİCHE, K., SOUEBNI, L., FAZAA, A., BETTAİEB, H., SELLAMİ, M., KASSAB, S., CHEKILI, S., ZARAOUI, L., ABDELGHANI, K., LAATAR, A. (2022). Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 85–93. https://ajindex.com/articles/447973

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18(13 Suppl):S295-302
  2. Sruamsiri R, Mahlich J, Tanaka E, Yamanaka H. Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey. Mod Rheumatol 2018;28:482-9
  3. Verstappen SM. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol 2015;29:495-511
  4. Fautrel B, Gaujoux-Viala C. Medical and economic aspects of rheumatoid arthritis. Bull Acad Natl Med 2012;196:1295-305
  5. Moreland LW, Bridges SL Jr. Early rheumatoid arthritis: A medical emergency? Am J Med 2001;111:498-500. 6. van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:274-9
  6. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 2006;55:864-72
  7. Stenger AA, Van Leeuwen MA, Houtman PM, Bruyn GA, Speerstra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63
  8. Dawes PT, Symmons DP. Short-term effects of antirheumatic drugs. Baillieres Clin Rheumatol 1992;6:117-40
  9. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14
  10. Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: From old to new perspectives. RMD Open 2019;5:e000870
  11. Fathi N, Abda EAM, Salim ZA, Kong K, Badsha H. Rheumatoid arthritis in a cross section of Egyptian patients. Ann Rheum Dis 2009;68(Suppl 3):422
  12. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77
  13. Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone